PIM
PBYI icon

Partner Investment Management’s Puma Biotechnology PBYI Stock Holding History

Partner Investment Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,800
Closed -$420K – 95
2017
Q2 		$420K Buy
+4,800
New +$269K 0.56% 56

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Partner Investment Management's PBYI Position: Q4 2019 in Review

Partner Investment Management sold out of Puma Biotechnology (PBYI) in Q4 2019, closing a stake of 33,866 shares — an estimated $365K sold.

Partner Investment Management first reported a position in PBYI in Q2 2016 and held it in 12 quarters. The position peaked at $2.61M in Q4 2017. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2019.

  • Partner Investment Management reported no remaining Puma Biotechnology position as of Q4 2019 after selling out during the quarter.
  • Partner Investment Management sold 33,866 Puma Biotechnology shares in Q4 2019, an estimated $365K.
  • Partner Investment Management first reported a position in Puma Biotechnology in Q2 2016 and held it in 12 quarters.
  • Partner Investment Management's Puma Biotechnology position peaked at $2.61M in Q4 2017.
  • 133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2019.

Based on Partner Investment Management's 13F filing for Q4 2019, filed 14 Feb 2020.